Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity
Journal Title: Journal of Clinical and Translational Research - Year 2017, Vol 3, Issue 1
Abstract
Background: Obesity is often associated with nonalcoholic fatty liver disease (NAFLD), which refers to a large spectrum of hepatic lesions including fatty liver, nonalcoholic steatohepatitis (NASH) and cirrhosis. Different investigations showed or suggested that obesity and NAFLD are able to increase the risk of hepatotoxicity of different drugs. Some of these drugs could induce more frequently an acute hepatitis in obese individuals whereas others could worsen pre-existing NAFLD. Aim: The main objective of the present review was to collect the available information regarding the role of NAFLD as risk factor for drug-induced hepatotoxicity. For this purpose, we performed a data-mining analysis using different queries including drug-induced liver injury (or DILI), drug-induced hepatotoxicity, fatty liver, nonalcoholic fatty liver disease (or NAFLD), steatosis and obesity. The main data from the collected articles are reported in this review and when available, some pathophysiological hypotheses are put forward. Relevance for patients: Drugs that could pose a potential risk in obese patients include compounds belonging to different pharmacological classes such as acetaminophen, halothane, methotrexate, rosiglitazone, stavudine and tamoxifen. For some of these drugs, experimental investigations in obese rodents confirmed the clinical observations and unveiled different pathophysiological mechanisms which could explain why these pharmaceuticals are particularly hepatotoxic in obesity and NAFLD. Other drugs such as pentoxifylline, phenobarbital and omeprazole might also pose a risk but more investigations are required to determine whether this risk is significant or not. Because obese people often take several drugs for the treatment of different obesity-related diseases such as type 2 diabetes, hyperlipidemia and coronary heart disease, it is urgent to identify the main pharmaceuticals that can cause acute hepatitis on a fatty liver background or induce NAFLD worsening.
Authors and Affiliations
Julie Massart, Karima Begriche, Caroline Moreau, Bernard Fromenty
Keywords
Related Articles
- EP ID EP678786
- DOI -
- Views 224
- Downloads 0
Layer-by-layer heparinization of decellularized liver matrices to reduce thrombogenicity of tissue engineered grafts
Background: Tissue–engineered liver grafts may offer a viable alternative to orthotopic liver transplantation and help overcome the donor organ shortage. Decellularized liver matrices (DLM) have a preserved vasculature a...
Prevalence, morphological variation and ossification of sesamoid bones of the forefoot: a retrospective radiographic study of 8,716 Chinese subjects
Background and Aim: Previous studies provided evidence of a genetic basis for the occurrence of sesamoids bone in the foot among different ethnic populations. However, information for the Chinese population has not been...
Higher blood pressure and lower cardiac vagal activity in obese young individuals in supine and seated position
Background: Obesity triggers alterations in hemodynamic and autonomic control. There are few studies that investigate the effects of overweight and obesity in early adulthood on hemodynamic and autonomic variables. Aim:...
Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives
Mitochondria are critical cellular organelles for energy generation and are now also recognized as playing important roles in cellular signaling. Their central role in energy metabolism, as well as their high abundance i...
Anti-cancer effects of aloe-emodin: a systematic review
Background: Anthraquinones are a possible treatment option for oncological patients due to their anti-cancer properties. Cancer patients often exhaust a plethora of resources that ultimately fail to provide fully curativ...